255 related articles for article (PubMed ID: 15496400)
1. Negative regulation of JNK signaling by the tumor suppressor CYLD.
Reiley W; Zhang M; Sun SC
J Biol Chem; 2004 Dec; 279(53):55161-7. PubMed ID: 15496400
[TBL] [Abstract][Full Text] [Related]
2. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
[TBL] [Abstract][Full Text] [Related]
3. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
Yoshida H; Jono H; Kai H; Li JD
J Biol Chem; 2005 Dec; 280(49):41111-21. PubMed ID: 16230348
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.
Jono H; Lim JH; Chen LF; Xu H; Trompouki E; Pan ZK; Mosialos G; Li JD
J Biol Chem; 2004 Aug; 279(35):36171-4. PubMed ID: 15226292
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.
Reiley W; Zhang M; Wu X; Granger E; Sun SC
Mol Cell Biol; 2005 May; 25(10):3886-95. PubMed ID: 15870263
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
7. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
[TBL] [Abstract][Full Text] [Related]
8. A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells.
Liu S; Lv J; Han L; Ichikawa T; Wang W; Li S; Wang XL; Tang D; Cui T
Biochem Biophys Res Commun; 2012 Mar; 420(1):78-83. PubMed ID: 22406061
[TBL] [Abstract][Full Text] [Related]
9. CYLD: a multifunctional deubiquitinase.
Glittenberg M; Ligoxygakis P
Fly (Austin); 2007; 1(6):330-2. PubMed ID: 18820455
[TBL] [Abstract][Full Text] [Related]
10. Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA.
Wang X; Mader MM; Toth JE; Yu X; Jin N; Campbell RM; Smallwood JK; Christe ME; Chatterjee A; Goodson T; Vlahos CJ; Matter WF; Bloem LJ
J Biol Chem; 2005 May; 280(19):19298-305. PubMed ID: 15737997
[TBL] [Abstract][Full Text] [Related]
11. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
12. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.
Brummelkamp TR; Nijman SM; Dirac AM; Bernards R
Nature; 2003 Aug; 424(6950):797-801. PubMed ID: 12917690
[TBL] [Abstract][Full Text] [Related]
13. Cordycepin promotes apoptosis in renal carcinoma cells by activating the MKK7-JNK signaling pathway through inhibition of c-FLIPL expression.
Hwang IH; Oh SY; Jang HJ; Jo E; Joo JC; Lee KB; Yoo HS; Lee MY; Park SJ; Jang IS
PLoS One; 2017; 12(10):e0186489. PubMed ID: 29045468
[TBL] [Abstract][Full Text] [Related]
14. The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway.
Chen AJ; Zhou G; Juan T; Colicos SM; Cannon JP; Cabriera-Hansen M; Meyer CF; Jurecic R; Copeland NG; Gilbert DJ; Jenkins NA; Fletcher F; Tan TH; Belmont JW
J Biol Chem; 2002 Sep; 277(39):36592-601. PubMed ID: 12138158
[TBL] [Abstract][Full Text] [Related]
15. Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation.
Munroe ME; Bishop GA
J Biol Chem; 2004 Dec; 279(51):53222-31. PubMed ID: 15485859
[TBL] [Abstract][Full Text] [Related]
16. CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.
Miliani de Marval P; Lutfeali S; Jin JY; Leshin B; Selim MA; Zhang JY
Cancer Prev Res (Phila); 2011 Jun; 4(6):851-9. PubMed ID: 21478324
[TBL] [Abstract][Full Text] [Related]
17. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
18. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
19. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines.
Tournier C; Dong C; Turner TK; Jones SN; Flavell RA; Davis RJ
Genes Dev; 2001 Jun; 15(11):1419-26. PubMed ID: 11390361
[TBL] [Abstract][Full Text] [Related]
20. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase.
Manna SK; Sah NK; Newman RA; Cisneros A; Aggarwal BB
Cancer Res; 2000 Jul; 60(14):3838-47. PubMed ID: 10919658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
